Evaluation of myocardial iron overload using cardiovascular magnetic resonance imaging

Hellenic Journal of Cardiology

Volumn 52, Issue 5, 2011, Pages 385-390

  Mavrogeni, Sophie ^a   Pepe, Alessia ^b   Lombardi, Massimo ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b CNR   (Italy)

Author keywords

Iron overload; Magnetic resonance imaging

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CHELATION THERAPY; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; EDITORIAL; ELECTROCARDIOGRAM; FERRITIN BLOOD LEVEL; HEARING DISORDER; HEART DISEASE; HEART MUSCLE BIOPSY; HEMOSIDEROSIS; HUMAN; INJECTION SITE REACTION; IRON ABSORPTION; IRON BINDING CAPACITY; IRON CARDIOMYOPATHY; IRON OVERLOAD; LIVER BIOPSY; MONOTHERAPY; MYOCARDITIS; NEUROLOGICAL COMPLICATION; THALASSEMIA MAJOR; VISUAL DISORDER;

BETA-THALASSEMIA; CARDIOMYOPATHIES; HUMANS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING;

EID: 80053125750     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (58)

1. Bunn HF. Disorders of hemoglobin. In: Wilson et al, editors. Harrison's principles of Internal Medicine. Mc Graw-Hill, Intern Ed, 12th Edition; 1991. p. 1543-1552.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89: 1187-1193.
3. Sonakul D, Thakerngpol K, Pacharee P. Cardiac pathology in 76 thalassemic patients. Birth Defects Orig Artic Ser. 1988; 23: 177-191.
4. Ohene-Frempong K, Schwartz E. Clinical features of thalassemia. Pediatr Clin North Am. 1980; 27: 403-420.
5. Dwyer J, Wood C, McNamara J, et al. Abnormalities in the immune system of children with beta-thalassaemia major. Clin Exp Immunol. 1987; 68: 621-629.
6. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation. 1995; 91: 66-71.
7. Kremastinos DT. Beta-thalassemia heart disease: is it time for its recognition as a distinct cardiomyopathy? Hellenic J Cardiol. 2008; 49: 451-452.
8. Kremastinos DT. Heart failure in beta-thalassaemia: a local or universal health problem? Hellenic J Cardiol. 2007; 48: 189-190.
9. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in pa tients with thalassemia major in Greece. Ann N Y Acad Sci. 2005; 1054: 445-450.
10. Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit. Eur J Haematol. 2009; 82: 381-387.
11. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331: 574-578.
12. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004; 73: 359-366.
13. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008; 10: 12.
14. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002; 360: 516-520.
15. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2. Eur J Haematol. 2006; 76: 183-192.
16. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006; 107: 3436-3441.
17. Galia M, Midiri M, Bartolotta V, et al. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin. 2003; 27: 63-76.
18. Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011; 96: 41-47.
19. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo- controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007; 115: 1876-1884.
20. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006; 30: 239-249.
21. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010; 115: 2364-2371.
22. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010; 116: 537-543.
23. Mavrogeni S, Gotsis ED, Berdousi E, et al. Myocardial and hepatic T2 magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation. Int J Cardiovasc Imaging. 2007; 23: 739-745.
24. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002; 100: 17-21.
25. Crosby WH. Editorial: Serum ferritin fails to indicate hemochromatosis-- nothing gold can stay. N Engl J Med. 1976; 294: 333-334.
26. Johnston DL, Rice L, Vick GW, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med. 1989; 87: 40-47.
27. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331: 574-578.
28. Kremastinos DT, Rentoukas E, Mavrogeni S, Kyriakides ZS, Politis C, Toutouzas P. Left ventricular filling pattern in betathalassaemia major-a Doppler echocardiographic study. Eur Heart J. 1993; 14: 351-357.
29. Guyader D, Gandon Y, Robert JY, et al. Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis. J Hepatol. 1992; 15: 304-308.
30. Garceau P, Nguyen ET, Carasso S, et al. Quantification of myocardial iron deposition by two-dimensional speckle tracking in patients with β-thalassaemia major and Blackfan-Diamond anaemia. Heart. 2011; 97: 388-393.
31. Hazirolan T, Akpinar B, Unal S, Gümrük F, Haliloglu M, Alibek S. Value of dual energy computed tomography for detection of myocardial iron deposition in thalassaemia patients: initial experience. Eur J Radiol. 2008; 68: 442-445.
32. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982; 307: 1671-1675.
33. Drayer B, Burger P, Darwin R, Riederer S, Herfkens R, Johnson GA. Magnetic resonance imaging of brain iron. AJR Am J Roentgenol 1986; 147: 103-110.
34. Doyle FH, Pennock JM, Banks LM, et al. Nuclear magnetic resonance imaging of the liver: initial experience. AJR Am J Roentgenol. 1982; 138: 193-200.
35. Berardino ME, Small W, Goldstein J, et al. Multiple NMR T2 relaxation values in human liver tissue. AJR Am J Roentgenol 1983; 141: 1203-1208.
36. Brasch RC, Wesbey G, Gooding CA, Koerper M. MRI of transfusional hemosiderosis in children with thalassemia major. Radiology 1984; 15: 767-771.
37. Vymazal J, Brooks RA, Zak O, McRill C, Shen C, Di Chiro G. T1 and T2 of ferritin at different field strengths: Effect on MRI. Magn Reson Med. 1992; 27: 368-374.
38. Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1995; 154: 137-142.
39. Gomori J, Grossman R, Drott H. MR relaxation times and iron content of thalassemic spleens: an in vitro study. AJR Am J Roentgenol 1988; 150: 567-569.
40. Liu P, Henkelman M, Joshi J, et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Can J Cardiol. 1996; 12: 155-164.
41. Mavrogeni SI, Markussis V, Kaklamanis L, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol. 2005; 75: 241-247.
42. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in b-thalassemia. MAGMA. 1998; 6: 7-12.
43. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2- star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001; 22: 2171-2179.
44. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Multi-center validation of the transferability of the magnetic resonance T2 technique for the quantification of tissue iron. Haematologica. 2006; 91: 1388-1391.
45. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2 cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003; 18: 33-39.
46. Ramazzotti A, Pepe A, Positano V, et al. Multicenter validation of the magnetic resonance T2 technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging. 2009; 30: 62-68.
47. Pepe A, Positano V, Santarelli MF, et al. Multislice multiecho T2 cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006; 23: 662-668.
48. Positano V, Pepe A, Santarelli MF, et al. Standardized T2 map of normal human heart in vivo to correct T2 segmental artefacts. NMR Biomed. 2007; 20: 578-590.
49. Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007; 78: 52-57.
50. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006; 107: 3436-3441.
51. Galia M, Midiri M, Bartolotta V, et al. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study. Hemoglobin. 2003; 27: 63-76.
52. Carpenter J-P, Pennell DJ. Role of T2 magnetic resonance in monitoring iron chelation therapy. Acta Haematol. 2009; 122: 146-154.
53. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2 cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008; 10: 42.
54. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo- controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007; 115: 1876-1884.
55. Mavrogeni S, Manoussakis MN. Myocarditis as a complication of influenza A (H1N1): evaluation using cardiovascular magnetic resonance imaging. Hellenic J Cardiol. 2010; 51: 379-380.
56. Kirschbaum SW, van Geuns R-JM. Cardiac magnetic resonance imaging to detect and evaluate ischemic heart disease. Hellenic J Cardiol. 2009; 50: 119-126.
57. Rovai D, Morales MA, Di Bella G, et al. Clinical diagnosis of left ventricular dilatation and dysfunction in the age of technology. Eur J Heart Fail. 2007; 9: 723-729.
58. Pepe A, Positano V, Capra M, et al. Prevalence and clinical- Instrumental correlates of myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassemia major. Heart 2009, 95, 1688-1693.